11.69
0.04 (0.39%)
| Previous Close | 11.64 |
| Open | 11.62 |
| Volume | 623,685 |
| Avg. Volume (3M) | 5,806,141 |
| Market Cap | 7,979,476,480 |
| Price / Sales | 365.05 |
| Price / Book | 1.87 |
| 52 Weeks Range | |
| Earnings Date | 10 Nov 2025 |
| Operating Margin (TTM) | -4,823.84% |
| Diluted EPS (TTM) | -0.750 |
| Quarterly Revenue Growth (YOY) | -16.10% |
| Quarterly Earnings Growth (YOY) | -96.70% |
| Total Debt/Equity (MRQ) | 1.93% |
| Current Ratio (MRQ) | 33.47 |
| Operating Cash Flow (TTM) | -839.45 M |
| Levered Free Cash Flow (TTM) | -375.20 M |
| Return on Assets (TTM) | -10.73% |
| Return on Equity (TTM) | -12.54% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bearish |
| Biotechnology (Global) | Mixed | Bearish | |
| Stock | Roivant Sciences Ltd. | Mixed | Mixed |
AIStockmoo Score
| Analyst Consensus | 2.5 |
| Insider Activity | NA |
| Price Volatility | 1.0 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | 4.0 |
| Average | 2.50 |
|
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Mid Growth |
| % Held by Insiders | 30.31% |
| % Held by Institutions | 83.49% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Qvt Financial Lp | 30 Jun 2025 | 29,381,635 |
| Patient Square Capital Lp | 30 Jun 2025 | 12,480,000 |
| Anchorage Capital Group, L.L.C. | 30 Jun 2025 | 4,832,642 |
| 52 Weeks Range | ||
| Median | 18.00 (54.04%) | |
| Total | 1 Buy | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| HC Wainwright & Co. | 18 Jun 2025 | 18.00 (54.04%) | Buy | 11.44 |
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |